EUVIMEDEUVIMED entdecken
Crossref

Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry

Andrea Lee Cervi, Darrin Applegate, Scott M Stevens, Scott C Woller, Lisa M Baumann Kreuziger, Kavya Punchhalapalli, Tzu-Fei Wang, Ramon Lecumberri, Kaity Greco, Yuxin Bai, Samantha Bolger, Stephanie Fontyn und 3 weitere

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.09.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Andrea Lee Cervi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Venous Thrombosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: LEO Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with acute deep vein thrombosis (DVT) treated with catheter-based thrombolysis and venous stenting, poststenting anticoagulant management is uncertain. OBJECTIVES: To determine the type and duration of antithrombotic therapy used in patients who have received venous stents for treatment of acute lower extremity DVT. METHODS: We created an international registry of patients with leg DVT from 2005 to 2019 who received venous stents as part of their acute management. We collected data on baseline clinical characteristics and pre-venous and post-venous stent antithrombotic therapy. RESULTS: We studied 173 patients with venous stents: 101 (58%) were aged ≤50 years, 105 (61%) were female, and 128 (74%) had risk factors for thrombotic disease. DVT was iliofemoral in 150 (87%) patients, and catheter-based treatment was given within 7 days of diagnosis in 92 (53%) patients. After venous stenting, 109 (63%) patients received anticoagulant-only therapy with a direct oral anticoagulant (29%), warfarin (22%), or low-molecular-weight heparin (10%), and 59 (34%) received anticoagulant-antiplatelet therapy. In patients taking anticoagulant-only therapy, 29% received indefinite treatment; in patients on anticoagulant-antiplatelet therapy, 19% received indefinite treatment. Factors associated with combined anticoagulant-antiplatelet therapy vs anticoagulant-only therapy were use of thrombolytic, thrombectomy, and aspiration interventions (odds ratio [OR], 5.11; 95% CI, 1.45-18.05); use of balloon angioplasty (OR, 2.62; 95% CI, 1.20-5.76); and immediate stent restenosis (OR, 7.2; 95% CI, 1.45-5.89). CONCLUSION: Anticoagulant therapy without concomitant antiplatelet therapy appears to be the most common antithrombotic strategy in patients with DVT and venous stenting. More research is needed to determine outcomes of venous stenting in relation to antithrombotic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsVenous ThrombosisHumansFemaleMaleThrombolytic TherapyPlatelet Aggregation InhibitorsTreatment OutcomeFemoral VeinAnticoagulantsStentsRetrospective Studies

Stichwörter der Autor:innen

anticoagulantsfactor Xa inhibitorsstentsthrombolytic therapyvenous thrombosis

Substanzen

Fibrinolytic AgentsPlatelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Intermountain Healthcare, Murray, Utah, USA.
  • Intermountain Healthcare, Murray, Utah, USA; University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Förderung

  • LEO Pharma

Zitieren

APA

Lee Cervi, A., Applegate, D., Stevens, S. M., Woller, S. C., Baumann Kreuziger, L. M., Punchhalapalli, K., Wang, T. F., Lecumberri, R., Greco, K., Bai, Y., Bolger, S., Fontyn, S., Schulman, S., Foster, G., & Douketis, J. D. (2023). Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.09.008

Vancouver

Lee Cervi A, Applegate D, Stevens SM, Woller SC, Baumann Kreuziger LM, Punchhalapalli K, et al. Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.09.008

BibTeX
@article{LeeCervi2023,
  author = {Lee Cervi, Andrea and Applegate, Darrin and Stevens, Scott M and Woller, Scott C and Baumann Kreuziger, Lisa M and Punchhalapalli, Kavya and Wang, Tzu-Fei and Lecumberri, Ramon and Greco, Kaity and Bai, Yuxin and Bolger, Samantha and Fontyn, Stephanie and Schulman, Sam and Foster, Gary and Douketis, James Demetrios},
  title = {Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.09.008}
}
Kostenlos starten →